A kind of immunomodulator sustained-release agent and preparation method thereof
A technology of sustained-release tablets and sustained-release layers, which is applied in the directions of pill delivery, pharmaceutical formulations, and medical preparations with inactive ingredients, etc., can solve the problems of affecting the therapeutic effect, low blood drug concentration, technical difficulty, etc., and prolong the action time. , The effect of simple prescription and simple process operation
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0136] A lenalidomide sustained-release tablet, comprising the following components (calculated in 1000 tablets):
[0137] Lenalidomide 25.00 g
[0138] Hypromellose (3000mPa•s-8000mPa•s)
[0139] (sustained release matrix material) 200.00 g
[0140] Povidone (adhesive) 25.00 g
[0141] Microcrystalline cellulose (filler) 112.50 g
[0142] Mannitol (bulking agent) 100.00 g
[0143] Povidone (solubilizer) 25.00 g
[0144] Talc powder (glidant) 5.00 g
[0145]Magnesium stearate (lubricant) 7.50 g
[0146] Opadry II (film coating material) 15.00 g
[0147] The method for preparing the above-mentioned lenalidomide sustained-release tablet comprises the following steps:
[0148] (1) According to the prescription, lenalidomide fine powder, slow-release matrix material, adhesive, filler and solubilizer are passed through a 40-mesh sieve, and the glidant and lubricant are passed through a 80-mesh sieve;
[0149] (2) Accurately weigh lenalidomide, sustained-release matrix mate...
Embodiment 2
[0156] A lenalidomide sustained-release tablet, comprising the following components (calculated in 1000 tablets):
[0157] Lenalidomide 25.00 g
[0158] Hypromellose (12000mPa•s-21000mPa•s)
[0159] (sustained release matrix material) 150.00 g
[0160] Pregelatinized starch (binder) 100.00 g
[0161] Calcium hydrogen phosphate (filler) 635.00 g
[0162] Povidone (solubilizer) 10.00 g
[0163] Talc powder (glidant) 50.00 g
[0164] Magnesium stearate (lubricant) 30.00 g
[0165] Opadry II (film coating material) 30.00 g
[0166] The method for preparing the above-mentioned lenalidomide sustained-release tablet is the same as that in Example 1.
Embodiment 3
[0168] A lenalidomide sustained-release tablet, comprising the following components (calculated in 1000 tablets):
[0169] Lenalidomide 25.00 g
[0170] Carbomer (sustained release matrix material) 180.00 g
[0171] Povidone (adhesive) 15.00 g
[0172] Compressible starch (filler) 52.50 g
[0173] Hydroxypropyl-β-cyclodextrin (solubilizer) 65.00 g
[0174] Micronized silica gel (glidant) 1.50 g
[0175] Magnesium stearate (lubricant) 1.50 g
[0176] Opadry II (film coating material) 12.00 g
[0177] The method for preparing the above-mentioned lenalidomide sustained-release tablet is the same as that in Example 1.
PUM
Property | Measurement | Unit |
---|---|---|
viscosity | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com